A Randomized Trial of Closed-Loop Insulin Delivery Postpartum in Type 1 Diabetes

• DOI: 10.2337/dc23-0882
• Publication Date: 2023-10-12T19:22:43Z
• Authors: Lois E. Donovan; Denice S. Feig; Patricia Lemieux; Helen R. Murphy; Rhonda C. Bell; Ronald J. Sigal; Josephine Ho; Heidi Virtanen; Susan Crawford; Jennifer M. Yamamoto
• Keywords: Insulin pump; Insulin delivery

This study aimed to evaluate the efficacy of closed-loop insulin delivery postpartum.In this open-label, randomized controlled trial, postpartum individuals with type 1 diabetes were hybrid MiniMed 670G/770G system in automode or sensor-augmented pump therapy first 12-weeks followed by a continuation phase for all until 24 weeks postpartum.Eighteen participants (mean ± SD age 32 3.5 years, duration 22 7.3 and early pregnancy HbA1c 52 6.8 mmol/mol [6.9 0.9%]) completed follow-up. In phase, percent time range 70-180 mg/dL (3.9-10 mmol/L) did not differ between groups (79.2 8.7% vs. 78.2 6.0%; P = 0.41). Participants spent less <70 (3.9 <54 (3.0 (1.7 0.8% 5.5 3.3% [P < 0.001] 0.3 0.2% 1.1 0.9% 0.008]). Time >180 (10 was different (18.7 8.8% 15.9 7.7%; 0.21). those initially had after initiation (5.5 3.3 2.2%; 0.039). The group maintained similar glycemic metrics both phases. There no episodes diabetic ketoacidosis severe hypoglycemia either group.Women than therapy. safety concerns. These findings are reassuring use because its potential reduce hypoglycemia.